16 hours ago
Analysts Offer Insights on Healthcare Companies: Kuros Biosciences (OtherCSBTF), CSL (OtherCMXHF) and Roche Holding AG (OtherRHHVF)
There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Kuros Biosciences (CSBTF – Research Report), CSL (CMXHF – Research Report) and Roche Holding AG (RHHVF – Research Report) with bullish sentiments.
Confident Investing Starts Here:
Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Kuros Biosciences (CSBTF)
Kepler Capital analyst Christophe dombu maintained a Buy rating on Kuros Biosciences on June 16 and set a price target of CHF32.50. The company's shares closed last Wednesday at $33.22, close to its 52-week high of $36.10.
According to dombu is ranked #8486 out of 9621 analysts.
The the analyst consensus on Kuros Biosciences is currently a Hold rating.
CSL (CMXHF)
Morgan Stanley analyst David Bailey maintained a Buy rating on CSL today and set a price target of A$303.00. The company's shares closed last Tuesday at $148.56.
According to Bailey is a 4-star analyst with an average return of 16.4% and a 48.1% success rate. Bailey covers the Healthcare sector, focusing on stocks such as Fisher & Paykel Healthcare Corporation Limited, Ramsay Health Care, and Cochlear.
CSL has an analyst consensus of Strong Buy, with a price target consensus of $203.87, implying a 37.2% upside from current levels. In a report released yesterday, Jarden also maintained a Buy rating on the stock with a A$317.61 price target.
Roche Holding AG (RHHVF)
Kepler Capital analyst David Evans maintained a Buy rating on Roche Holding AG on June 16 and set a price target of CHF315.00. The company's shares closed last Tuesday at $321.13.
According to Evans is ranked #4919 out of 9621 analysts.
The word on The Street in general, suggests a Hold analyst consensus rating for Roche Holding AG with a $352.85 average price target, implying an 8.3% upside from current levels. In a report issued on June 16, UBS also maintained a Buy rating on the stock with a CHF314.00 price target.
